<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Genet</journal-id><journal-id journal-id-type="iso-abbrev">Front Genet</journal-id><journal-id journal-id-type="publisher-id">Front. Genet.</journal-id><journal-title-group><journal-title>Frontiers in Genetics</journal-title></journal-title-group><issn pub-type="epub">1664-8021</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5735066</article-id><article-id pub-id-type="doi">10.3389/fgene.2017.00216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Genetics</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Head</surname><given-names>Trajen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/473228/overview"/></contrib><contrib contrib-type="author"><name><surname>Daunert</surname><given-names>Sylvia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goldschmidt-Clermont</surname><given-names>Pascal J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine</institution>, <addr-line>Miami, FL</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Division of Cardiology, University of Miami Miller School of Medicine</institution>, <addr-line>Miami, FL</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Mingyi Wang, National Institutes of Health (NIH), United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Maria Markaki, Foundation for Research and Technology Hellas, Greece; Srinivas Ayyadevara, Central Arkansas Veterans Healthcare system, United States; Adelheid Kratzer, Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, Germany</p></fn><corresp id="fn001">*Correspondence: Pascal J. Goldschmidt-Clermont <email xlink:type="simple">pgoldschmidt@med.miami.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Genetics of Aging, a section of the journal Frontiers in Genetics</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>216</elocation-id><history><date date-type="received"><day>31</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Head, Daunert and Goldschmidt-Clermont.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Head, Daunert and Goldschmidt-Clermont</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>A considerable volume of research over the last decade has focused on understanding the fundamental mechanisms for the progression of atherosclerosis&#x02014;the underlying cause for the vast majority of all cardiovascular (CVD)-related complications. Aging is the dominant risk factor for clinically significant atherosclerotic lesion formation, yet the heightened impact of aging on the disease is not accounted for by changes in traditional risk factors, such as lack of physical activity, smoking, hypertension, hyperlipidemia, or diabetes mellitus. This review will examine the pathological and biochemical processes of atherosclerotic plaque formation and growth, with particular focus on the aging risk vis-a-vis arterial homeostasis. Particular focus will be placed on the impact of a number of important contributors to arterial homeostasis including bone marrow (BM)-derived vascular progenitor cells, differential monocyte subpopulations, and the role of cellular senescence. Finally, this review will explore many critical observations in the way the disease process has been reassessed both by clinicians and researchers, and will highlight recent advances in this field that have provided a greater understanding of this aging-driven disease.</p></abstract><kwd-group><kwd>atherosclerosis</kwd><kwd>cardiovascular disease</kwd><kwd>vascular repair</kwd><kwd>arterial homeostasis</kwd><kwd>aging</kwd><kwd>risk factors</kwd><kwd>bone marrow-derived vascular progenitor cells</kwd></kwd-group><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="110"/><page-count count="11"/><word-count count="9598"/></counts></article-meta></front><body><sec id="s1"><title>Atherosclerosis: ancient and inflammatory</title><p>Atherosclerosis is defined by the formation and growth of plaques within the arterial lumen with concurrent loss of vascular elasticity. Eventually, this condition can lead to consequent blood flow reduction through the affected vessel, and has long been associated with CVD-related death. Around the year 1505, Leonardo da Vinci recorded his observations of a &#x0201c;parched and shrunk and withered &#x02026; artery that feeds the heart,&#x0201d; attributing this as the cause of death of an elderly man who passed away &#x0201c;without any movement or sign of anything amiss&#x0201d; (McCurdy, <xref rid="B59" ref-type="bibr">1923</xref>). However, CVD remained a relatively uncommon cause of death until the dramatic surge in CVD mortality in the past 100 years, due primarily to marked and progressive increases in life expectancy, as a result of improved sanitation and public health, with a staggering reduction in communicable diseases and violent deaths. During this time period, numerous traditional lifestyle-associated CVD risk factors were identified and increased in prevalence, leading many to believe that atherosclerosis is an exclusively lifestyle-dependent modern disease. However, recent reports have challenged this view, demonstrating that mummies from various ancient societies&#x02014;from as much as 5,300 years ago&#x02014;exhibited a high prevalence of arterial changes compatible with atherosclerosis (Thompson et al., <xref rid="B87" ref-type="bibr">2013</xref>; Clarke et al., <xref rid="B15" ref-type="bibr">2014</xref>; Thomas et al., <xref rid="B85" ref-type="bibr">2014</xref>; Zink et al., <xref rid="B110" ref-type="bibr">2014</xref>). Additionally, a single nucleotide polymorphism (SNP) recently shown to be a genetic risk factor for CVD (minor allele of rs10757274 on chromosome 9p21) was detected in at least one of these mummies, despite the fact that it was initially believed that this gene modification arose much later in history (Zink et al., <xref rid="B110" ref-type="bibr">2014</xref>). Many putative mechanisms have been considered to account for the presence of CVD that far back in human history (Thompson et al., <xref rid="B87" ref-type="bibr">2013</xref>; Thomas et al., <xref rid="B85" ref-type="bibr">2014</xref>). In contrast, risk factors most commonly associated with disease in modern populations include modifiable risks&#x02014;such as tobacco use, obesity, diet, and physical inactivity&#x02014;and non-modifiable risks&#x02014;including age, gender, numerous identified SNPs in germ cells, and race (Yusuf et al., <xref rid="B106" ref-type="bibr">2004</xref>; Goldschmidt-Clermont et al., <xref rid="B31" ref-type="bibr">2012</xref>). Algorithms designed to interpret these factors and provide relative individual risk scores [Framingham (D'Agostino et al., <xref rid="B16" ref-type="bibr">2008</xref>), QRISK&#x000ae;2-2016 (Hippisley-Cox et al., <xref rid="B35" ref-type="bibr">2008</xref>), ACC/AHA ASCVD Goff et al., <xref rid="B28" ref-type="bibr">2014</xref>] have concluded that the strongest risk factor for atherosclerosis and CVD is indisputably age; using existing algorithms, simply increasing age&#x02014;while holding all other variables constant&#x02014;results in a marked increase in risk for CVD (Rauscher et al., <xref rid="B74" ref-type="bibr">2003</xref>; Karra et al., <xref rid="B40" ref-type="bibr">2005</xref>; Goldschmidt-Clermont et al., <xref rid="B31" ref-type="bibr">2012</xref>; Madonna et al., <xref rid="B56" ref-type="bibr">2016</xref>). The average annual rates of first CVD events for men increase over 20-fold or more between the age groups 35&#x02013;44 (incidence of 3 per 1,000) and 85&#x02013;94 (incidence of 74 per 1,000), while similar rates are observed in women ~10 years later in life (Benjamin et al., <xref rid="B5" ref-type="bibr">2017</xref>). Similarly, the average age of myocardial infarction is 65 and 72 for men and women, respectively (Members et al., <xref rid="B63" ref-type="bibr">2016</xref>). These acute clinical events occurring at advanced ages often manifest in the absence of associated symptoms, and are frequently fatal (Myerburg and Junttila, <xref rid="B66" ref-type="bibr">2012</xref>). However, atherosclerosis itself&#x02014;as the principal mechanism for the majority of these events&#x02014;is a chronic, inflammatory, progressive disease with initial manifestations beginning at young ages (McGill et al., <xref rid="B60" ref-type="bibr">2000</xref>; Zieske et al., <xref rid="B109" ref-type="bibr">2002</xref>; Hong, <xref rid="B36" ref-type="bibr">2010</xref>). Evidence of the disease has been reported in multiple arterial regions in children under the age of 10, and in the aortas of individuals less than a year old (McGill et al., <xref rid="B60" ref-type="bibr">2000</xref>; Hong, <xref rid="B36" ref-type="bibr">2010</xref>). Advanced lesions of atherosclerosis have been detected in the arteries, including coronaries, of US military even at a young age (Enos et al., <xref rid="B20" ref-type="bibr">1953</xref>; Webber et al., <xref rid="B95" ref-type="bibr">2012</xref>). Importantly, although the results of these studies may not be directly comparable to the general population for reasons such as risk factor disparity between groups (notably smoking and obesity), they provide two important insights to disease prevalence over the past several decades: first, that disease prevalence has appreciably declined during this time, and, second, that onset of disease occurs at an early age and has potential to progress rapidly with age (Levy, <xref rid="B45" ref-type="bibr">2012</xref>).</p><p>Historically, atherosclerosis was often viewed exclusively as the result of dyslipidemia. Both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) play critical roles in the transport of cholesterol and have been implicated in atherosclerosis (Fisher et al., <xref rid="B24" ref-type="bibr">2012</xref>; Ference et al., <xref rid="B23" ref-type="bibr">2017</xref>). Specifically, normal levels of HDL and HDL-cholesterol (HDL-C)&#x02014;often called the &#x0201c;good cholesterol&#x0201d;&#x02014;are associated with a variety of antiatherogenic processes and reduced levels of CVD overall (Fisher et al., <xref rid="B24" ref-type="bibr">2012</xref>; Rosenson et al., <xref rid="B76" ref-type="bibr">2016</xref>). In contrast, elevated levels of LDL and LDL-cholesterol (LDL-C) have been implicated in atherosclerosis progression (Fisher et al., <xref rid="B24" ref-type="bibr">2012</xref>; Ference et al., <xref rid="B23" ref-type="bibr">2017</xref>). However, we now know that elevated circulating LDL alone is generally insufficient to account for the observed extent of disease and is responsible for at most half of arterial lesions of atherosclerosis in elderly people, while disease can be found even in the complete absence of hyperlipidemia (Libby et al., <xref rid="B52" ref-type="bibr">2009</xref>; Wick and Grundtman, <xref rid="B97" ref-type="bibr">2012</xref>). Near the end of the twentieth century, the notion that atherosclerosis was a fundamentally inflammatory disease began to gain popularity, catalyzed largely by pathologist Russel Ross' pioneering report, &#x0201c;Atherosclerosis&#x02014;An Inflammatory Disease,&#x0201d; and by the work of Peter Libby (Ross, <xref rid="B77" ref-type="bibr">1999</xref>; Libby, <xref rid="B49" ref-type="bibr">2002</xref>; Libby et al., <xref rid="B53" ref-type="bibr">2002</xref>). The formation and progression of atherosclerotic plaques as we understand today largely support Ross' own &#x0201c;response-to-injury&#x0201d; hypothesis, implicating plaque formation as a consequence of focal endothelial cell (EC) injury and inflammation (Tuttolomondo et al., <xref rid="B89" ref-type="bibr">2012</xref>; Wick and Grundtman, <xref rid="B97" ref-type="bibr">2012</xref>). However, as more of the underlying mechanisms and pathways controlling atherosclerosis are identified, it becomes clear that this disease does not simply follow a single, forward direction of irreversible progression. In contrast, it is evident now that atherosclerosis is the result of a myriad of independent pathways and their complex interactions (Libby, <xref rid="B50" ref-type="bibr">2016</xref>). These pathways involve a multitude of various players, including various subpopulations of immune competent cells such as monocytes and macrophages, bone marrow (BM)-derived progenitor cells, chemokines and receptors, and cellular and subcellular fates including protein aggregation, cellular senescence, and apoptosis. In the following sections, each of these various aspects of atherosclerosis&#x02014;and the ever-present effect of aging on these pathways and players, and beyond&#x02014;will be explored.</p></sec><sec id="s2"><title>Arterial homeostasis, aging, and balance between injury and repair</title><p>Recently, it has been shown that genetic expression profiles and epigenetic modifications exert complex control and regulatory mechanisms for atherosclerosis (Karra et al., <xref rid="B40" ref-type="bibr">2005</xref>; Dunn et al., <xref rid="B19" ref-type="bibr">2014</xref>). Perhaps most critical to the understanding of this disease, are the recent findings that the most determinant factors for atherosclerosis progression are repair mechanisms, slowing or preventing the progression of disease, thus maintaining arterial homeostasis in spite of the presence of risk factors (Goldschmidt-Clermont, <xref rid="B29" ref-type="bibr">2003</xref>). Specifically, a growing body of evidence indicates that vascular repair, effected by BM-derived competent vascular progenitor cells that are programmed by chemokines, cytokines, matrix proteins, and growth factors, serves to counter the effects of endothelial injury and dysfunction that would otherwise lead to atherosclerosis progression (Rauscher et al., <xref rid="B74" ref-type="bibr">2003</xref>; Karra et al., <xref rid="B40" ref-type="bibr">2005</xref>; Madonna et al., <xref rid="B56" ref-type="bibr">2016</xref>). Using a well-established mouse model of atherosclerosis (severely hyperlipidemic, apolipoprotein E-deficient mice), it was shown that with aging, the capacity of BM-derived progenitor cells to repair arteries damaged by high lipid concentrations becomes impaired (Rauscher et al., <xref rid="B74" ref-type="bibr">2003</xref>), and that the development of atherosclerotic lesions occurs contemporaneously with the loss of repair capacity, and not simply when the severe hyperlipidemia begins (Karra et al., <xref rid="B40" ref-type="bibr">2005</xref>). Other work has identified the accumulation of senescent cells that produce pro-inflammatory cytokines and matrix metalloproteinases (MMPs) within atherosclerotic sites, but not in adjacent surrounding tissues (Childs et al., <xref rid="B11" ref-type="bibr">2016</xref>). Identification of these cells is generally dependent on the presence of p16<sup>INK4A</sup>, a cyclin-dependent kinase inhibitor responsible for cell cycle arrest in senescent cells (Baker et al., <xref rid="B3" ref-type="bibr">2011</xref>, <xref rid="B2" ref-type="bibr">2016</xref>). The factors released by senescent cells constitute a senescence-associated secretory phenotype (SASP), and have been shown to propagate atherosclerosis, while the selective targeting and elimination of these senescent cells (referred to as senolysis) has been shown to slow atherosclerotic lesions growth through reduction of inflammatory and adhesion factors (Childs et al., <xref rid="B12" ref-type="bibr">2017</xref>). Additional data suggests that BM-derived progenitor cells may protect from these effects through reduction of endothelial senescence (Rauscher et al., <xref rid="B74" ref-type="bibr">2003</xref>; Baker et al., <xref rid="B2" ref-type="bibr">2016</xref>; Childs et al., <xref rid="B11" ref-type="bibr">2016</xref>). Another interesting potential source of arterial aging to have emerged only recently involves the formation and accumulation of improperly folded proteins (Ayyadevara et al., <xref rid="B1" ref-type="bibr">2016</xref>). Although most commonly associated with neurodegenerative diseases such as Alzheimer's and Parkinson's disease, recent reports have indicated that dysfunctional processes of either protein production or degradation (resulting in aggregation) lead to proteotoxicity and have been linked to CVD (Willis and Patterson, <xref rid="B98" ref-type="bibr">2013</xref>). Additional reports have confirmed the presence of upregulated protein aggregates in models of aging and hypertension, identifying proteins within these aggregates known to be involved with CVD, and suggesting a variety of causes for aggregation including cellular senescence (Ayyadevara et al., <xref rid="B1" ref-type="bibr">2016</xref>). These findings may indicate a novel potential therapeutic target by examining the processes by which these protein aggregates form. Taken together, these results suggest that methods aimed at improving vascular repair, as an additional strategy to that of reducing vascular injury, may provide significantly heightened results in improving arterial homeostasis.</p><p>More recently, the crucial role of the BM in the maintenance of arterial homeostasis was further evidenced. Indeed, a novel impact of aging as a driver of cardiovascular disease risk was identified within hematopoietic progenitor cells. With aging, these cells have been shown to acquire somatic DNA mutations that provide competitive growth advantages and lead to an expanded pool of mutated clones (a process known as clonal hematopoiesis of intermediate potential, or CHIP; Steensma et al., <xref rid="B82" ref-type="bibr">2015</xref>). A recent study examined over 8,000 individuals from case-control studies, and revealed that elderly carriers of CHIP had nearly double the risk of coronary heart disease when compared to non-carriers (Jaiswal et al., <xref rid="B38" ref-type="bibr">2017</xref>). Moreover, this study demonstrated that the loss of function mutation of Tet2 (the second most commonly mutated gene in CHIP) led to accelerated atherosclerosis in mice, likely as a result of transcriptional modifications of associated macrophages (Jaiswal et al., <xref rid="B38" ref-type="bibr">2017</xref>). Interestingly, the loss of Tet2 also resulted in a highly induced expression of interleukin-1 beta (IL-1&#x003b2;), a well-characterized proinflammatory cytokine known to be involved in the development of atherosclerotic plaques (Jaiswal et al., <xref rid="B38" ref-type="bibr">2017</xref>; Ridker et al., <xref rid="B75" ref-type="bibr">2017</xref>). IL-1&#x003b2; is also activated via inflammasomes containing NOD-like receptors (NLRs; Furman et al., <xref rid="B25" ref-type="bibr">2017</xref>; Ridker et al., <xref rid="B75" ref-type="bibr">2017</xref>). Moreover, examination of inflammasome expression profiles revealed that individuals with profiles resulting in constitutive expression of IL-1&#x003b2; present characteristics (arterial stiffness, elevated blood pressure, oxidative stress, and chronic levels of inflammatory cytokines) associated with CVD, while inhibition of IL-1&#x003b2; resulted in significant reductions in recurrent CVD (Furman et al., <xref rid="B25" ref-type="bibr">2017</xref>; Ridker et al., <xref rid="B75" ref-type="bibr">2017</xref>). In addition to Tet2, mutated genes identified in this work include <italic>DNMT3A, ASXL1</italic>, and <italic>JAK2</italic>, and are associated with various processes including DNA methylation, chromatin remodeling, and cell proliferation. In similar fashion, other reports have demonstrated the critical importance of epigenetic modification of various genes involved in atherosclerosis. Specifically, it was shown that the methylation of CpG islands in the promoter region of the gene encoding for estrogen receptor alpha (ER&#x003b1;) is not only strongly associated with aging, but is responsible for the proliferation of smooth muscle cells involved in the growth of atherosclerotic plaques (Post et al., <xref rid="B71" ref-type="bibr">1999</xref>; Ying et al., <xref rid="B103" ref-type="bibr">2000</xref>).</p><p>Another critical area of interest with regards to aging and arterial homeostasis as it pertains to atherosclerosis is that of specific monocyte subpopulations. As recently as the late 1980s, it was widely believed that monocytes presented as a single population of cells (Stansfield and Ingram, <xref rid="B81" ref-type="bibr">2015</xref>). However, it was more recently demonstrated that these cells represent a heterogeneous mixture of cell subpopulations with distinct patterns in surface receptor expression as well as primary function in response to conditions such as atherosclerosis (Gordon and Taylor, <xref rid="B32" ref-type="bibr">2005</xref>). In mice, these subsets are often characterized as being either &#x0201c;inflammatory&#x0201d; (Ly6C<sup>hi</sup>) monocytes that play an innate roles in antimicrobial defense, or &#x0201c;resident&#x0201d; (Ly6C<sup>low</sup>) monocytes that actively patrol lumenal surface of the vasculature, removing damaged cells and debris, and generally promoting arterial homeostasis (Geissmann et al., <xref rid="B26" ref-type="bibr">2003</xref>; Woollard and Geissmann, <xref rid="B99" ref-type="bibr">2010</xref>; Thomas et al., <xref rid="B86" ref-type="bibr">2015</xref>). This patrolling behavior was first observed in the small vessels of the microcirculation, but has since been observed in larger vessels such as the carotid artery (Geissmann et al., <xref rid="B26" ref-type="bibr">2003</xref>; Quintar et al., <xref rid="B72" ref-type="bibr">2017</xref>). Importantly, it was shown that this patrolling behavior plays a potential role in endothelial protection, and that atherosclerosis can trigger an upregulation of the number of this subpopulation of monocytes (Quintar et al., <xref rid="B72" ref-type="bibr">2017</xref>). In humans, monocyte subpopulations are divided into three main categories, and share many characteristics with those identified in mice: the &#x0201c;classical&#x0201d; or &#x0201c;inflammatory&#x0201d; monocytes (CD14<sup>++</sup>CD16<sup>&#x02212;</sup>), the &#x0201c;non-classical&#x0201d; monocytes (CD14<sup>+</sup>CD16<sup>++</sup>) involved in arterial patrolling, and the more recently identified &#x0201c;intermediate&#x0201d; (CD14<sup>++</sup>CD16<sup>+</sup>) subpopulation of monocytes (Passlick et al., <xref rid="B69" ref-type="bibr">1989</xref>; Geissmann et al., <xref rid="B26" ref-type="bibr">2003</xref>; Woollard and Geissmann, <xref rid="B99" ref-type="bibr">2010</xref>; Ziegler-Heitbrock et al., <xref rid="B108" ref-type="bibr">2010</xref>; Stansfield and Ingram, <xref rid="B81" ref-type="bibr">2015</xref>). Human studies of atherosclerosis have mirrored those in mice, demonstrating that non-classical CD16<sup>+</sup> monocytes are primarily associated with disease, and further suggest roles for monocyte patrolling in injury healing and homeostasis (Stansfield and Ingram, <xref rid="B81" ref-type="bibr">2015</xref>). However, additional monocyte subpopulations have also been implicated in atherosclerosis progression in both mice and humans (Hilgendorf et al., <xref rid="B34" ref-type="bibr">2015</xref>; Stansfield and Ingram, <xref rid="B81" ref-type="bibr">2015</xref>). For example, although some results have shown that intermediate monocyte levels serve as an independent predictor of acute cardiovascular events such as stroke and myocardial infarction, additional population studies have demonstrated that increased levels of circulating classical monocytes serve as a reliable predictor of cardiovascular events regardless of age, sex, or other known traditional risk factors (Hilgendorf et al., <xref rid="B34" ref-type="bibr">2015</xref>). Additionally, classical Ly6C<sup>hi</sup> monocytes in mice were shown to infiltrate the endothelium at sites of injury, and contribute to foam cell formation (Swirski et al., <xref rid="B83" ref-type="bibr">2007</xref>; Stansfield and Ingram, <xref rid="B81" ref-type="bibr">2015</xref>). Ultimately, each of these subpopulations play varying roles in the formation, progression, and also regression of atherosclerosis.</p><p>As our understanding of this complex disease advances, it has become clear that there are numerous competing forces of disease progression and repair. It appears likely therefore that disease progression is the result of both the accumulation of signals and processes which exacerbate atherosclerotic inflammation, and which limit the efficiency of repair mechanisms, as a consequence of aging and exposure to traditional risk factors (Rauscher et al., <xref rid="B74" ref-type="bibr">2003</xref>; Goldschmidt-Clermont et al., <xref rid="B31" ref-type="bibr">2012</xref>). Given these recent advances in the understanding of this disease, it is important to review the proposed process by which arterial plaques form, and the importance of the competing forces of inflammation and repair throughout.</p></sec><sec id="s3"><title>Formation of the atherosclerotic plaque: local and distant (especially bone marrow function) modifiers</title><p>Although risk factors for atherosclerotic disease systemically affect all regions of the vasculature, plaque formation is not uniformly distributed. Instead, atherosclerotic plaques typically occur at a number of reproducible focal sites such as the inner wall of vessel curvature, the lateral walls of bifurcations, and near branch points (Pan, <xref rid="B68" ref-type="bibr">2009</xref>; Warboys et al., <xref rid="B94" ref-type="bibr">2011</xref>). An elegant theory to explain this plaque distribution disparity relies on the relative amount of shear stress exerted on the ECs in contact with the blood as it traverses the dynamic lumen geometry. There are two dominant forces exerted by blood on the inner lining of ECs within the vasculature. These hemodynamic forces include transmural pressure (a force exerted radially across the vessel wall, Figure <xref ref-type="fig" rid="F1">1A</xref>) and shear stress (the frictional force applied to the ECs by blood tangential to the direction of flow, Figure <xref ref-type="fig" rid="F1">1B</xref>). The value of endothelial shear stress (ESS, sometimes called wall shear stress or WSS) is determined as a function of blood viscosity (&#x003b7;) and its shear rate (<sup>&#x003b4;<italic>v</italic></sup>/<sub>&#x003b4;<italic>y</italic></sub>, a measure of the rate at which blood velocity increases from the endothelium toward the center of the vessel, Figure <xref ref-type="fig" rid="F1">1B</xref>). Blood flow in regions of relatively straight, uniform diameter vessels exhibits nearly laminar flow, resulting in ESS-values of 20&#x02013;70 dyne/cm<sup>2</sup> (2&#x02013;7 Pa) (Chatzizisis et al., <xref rid="B10" ref-type="bibr">2007</xref>; Chiu and Chien, <xref rid="B14" ref-type="bibr">2011</xref>). However, at the aforementioned locations prone to atherosclerotic plaque formation, the laminar flow characteristics are disrupted, causing regions of oscillatory or reversed flow and subsequent reduction in ESS (&#x0003c;10 dyne/cm<sup>2</sup>, Figure <xref ref-type="fig" rid="F1">1C</xref>). In these regions of disturbed flow, a number of events and responses to low shear stress occur that contribute to the process of atherosclerotic plaque formation.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Hemodynamic forces exerted on the arteries. <bold>(A)</bold> Trans-mural pressure exerted radially across the vessel wall. <bold>(B)</bold> Endothelial Shear Stress (ESS), determined as the product of blood viscosity (&#x003b7;) and its shear rate (<sup>&#x003b4;<italic>v</italic></sup>/<sub>&#x003b4;<italic>y</italic></sub>) such that ESS = &#x003b7; &#x02022; (<sup>&#x003b4;<italic>v</italic></sup>/<sub>&#x003b4;<italic>y</italic></sub>). <bold>(C)</bold> Typical sites of atherosclerotic plaque formation (lateral walls of bifurcations, inner wall of vessel curvature, and near branch points). Laminar flow in these regions is disrupted, causing oscillatory or reversed flow and subsequent low ESS. Comparison of the ability of bone marrow (BM)-derived vascular progenitor cells and other reparative factors to interact with injured endothelial cells under <bold>(D)</bold> laminar or <bold>(E)</bold> turbulent flow can be envisioned as the difference between landing a plane under calm or stormy conditions, respectively.</p></caption><graphic xlink:href="fgene-08-00216-g0001"/></fig><p>Following the &#x0201c;response-to-injury&#x0201d; hypothesis of atherosclerosis formation and progression, conditions of low overall ESS have been shown to facilitate additional insults to the endothelium leading to dysfunction. One such path initiated by low ESS is the sustained activation of sterol regulatory elements binding proteins (SREBPs). Once activated, these endoplasmic reticulum (ER)-bound transcription factors contribute to a strong inflammatory response and increase the expression of genes that encode for the LDL receptor (LDLR) (Liu et al., <xref rid="B55" ref-type="bibr">2002</xref>; Xiao et al., <xref rid="B100" ref-type="bibr">2013</xref>). In addition, a large volume of research has described the involvement of the lectin-like oxidized-LDL (ox-LDL) receptor-1 (LOX-1) in the initiation and progression of atherosclerosis (Mehta et al., <xref rid="B61" ref-type="bibr">2006</xref>; Mitra et al., <xref rid="B64" ref-type="bibr">2011</xref>; Pirillo et al., <xref rid="B70" ref-type="bibr">2013</xref>). LOX-1 has been reported to be responsible for the uptake and degradation of ox-LDL, and its expression has been shown <italic>in vitro</italic> to be upregulated by a number of atherosclerosis-related stimuli including shear stress, inflammatory cytokines [such as IL-1&#x003b2; and tumor necrosis factor alpha (TNF&#x003b1;)], and conditions such as hypertension (Mitra et al., <xref rid="B64" ref-type="bibr">2011</xref>; Pirillo et al., <xref rid="B70" ref-type="bibr">2013</xref>). Moreover, it was demonstrated that the deletion of LOX-1 reduced atherosclerosis in a LDLR knockout mouse model of disease (Mehta et al., <xref rid="B62" ref-type="bibr">2007</xref>). Yet another change associated with low ESS is the shift in EC morphology from tightly packed cells aligned with the direction of blood flow to a damaged morphology with cuboidal cells demonstrating no observed preferential alignment, and resulting in leakier junctions between cells (Davies, <xref rid="B18" ref-type="bibr">2009</xref>; Pan, <xref rid="B68" ref-type="bibr">2009</xref>; Linton et al., <xref rid="B54" ref-type="bibr">2015</xref>). This disorganized cell morphology is compounded by the loss of repair mechanisms affected by progenitor cells. As discussed previously, BM-derived progenitor repair cells play a critical role in protecting arteries against atherosclerosis. One reparative role played by these cells is the restoration of damaged endothelial tissue or engraftment into these damaged regions to reverse endothelial injury (Madonna et al., <xref rid="B56" ref-type="bibr">2016</xref>). Turbulent flow may disrupt the interaction between repair-competent cells in the blood and the arterial wall, thus limiting the effectiveness of the repair process (Figures <xref ref-type="fig" rid="F1">1D,E</xref>) (Xu, <xref rid="B101" ref-type="bibr">2009</xref>; Chiu and Chien, <xref rid="B14" ref-type="bibr">2011</xref>). It is also possible that low ESS prevents the wash-out of senescent ECs and macrophages, thus hindering their replacement by fresh such cells (Childs et al., <xref rid="B11" ref-type="bibr">2016</xref>). The net result of the up-regulation of LDLR and the increased cell permeability is a dramatic increase in levels of LDL infiltration in regions of low ESS (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage I) (Chatzizisis et al., <xref rid="B10" ref-type="bibr">2007</xref>). Additional pro-inflammatory pathways activated under conditions of low ESS include the mitogen-activated protein (MAP) kinase and nuclear factor &#x003ba;B (NF-&#x003ba;B) signaling pathways, while levels of miR-10a and its regulatory, anti-inflammatory effects on the NF-&#x003ba;B pathway are attenuated under these conditions (Fang et al., <xref rid="B22" ref-type="bibr">2010</xref>; Bryan et al., <xref rid="B8" ref-type="bibr">2014</xref>). Recently, this strictly dichotomous view of &#x0201c;low&#x0201d; and &#x0201c;high&#x0201d; ESS and its effect on the endothelium and atherosclerosis has been revisited, and it is now suggested that&#x02014;while physiological values of ESS appear to be atheroprotective&#x02014;both &#x0201c;low&#x0201d; and &#x0201c;high&#x0201d; shear stress outside this physiological range may lead to atherosclerosis progression (Hung et al., <xref rid="B37" ref-type="bibr">2015</xref>; Eshtehardi and Teng, <xref rid="B21" ref-type="bibr">2016</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Formation and progression of an atherosclerotic plaque. As an inflammatory disease, the initial stages of atherosclerosis involve an inflammatory insult to the endothelial cells lining the artery lumen. Bone marrow (BM)-derived progenitor cells have been shown to be critical in responding to vascular injury, effecting vascular repair and maintaining homeostasis. In the absence of vascular repair, injured endothelial cells begin to express adhesion molecules that facilitate the transmigration of monocytes into the vessel intima. These monocytes then differentiate into macrophages and begin engulfing lipid and lipid products, forming foam cells. As foam cells aggregate, they form the characteristic fatty streak, while many macrophages begin to undergo apoptosis. Inefficient clearance of apoptotic macrophages leads to secondary necrosis, resulting in a growing lipid-rich necrotic core. In response to the growing lesion, smooth muscle cells migrate to the intima, helping to form the overlying fibrous cap. Rupture of this cap can expose the necrotic core, leading to thrombus formation and subsequent acute cardiovascular events.</p></caption><graphic xlink:href="fgene-08-00216-g0002"/></fig><p>The combined net result of declining vascular repair mechanisms coupled with endothelial inflammation and the activation of ECs is the increased capture of circulating monocytes. This process, known as the leukocyte adhesion cascade, begins with the interaction of monocytes and displayed adhesion molecules in the regions of inflammation, leading to the stepwise rolling, firm adhesion, and transmigration of the monocyte into the vascular intima (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage II) (Ley et al., <xref rid="B46" ref-type="bibr">2007</xref>; Gerhardt and Ley, <xref rid="B27" ref-type="bibr">2015</xref>). Monocyte recruitment is largely directed by the presence of EC-derived chemokines (including CCL5, CCL2, and CX<sub>3</sub>CL1), their respective receptors (including CCR2, CXCR3, CX<sub>3</sub>CR1, and others), and various adhesion molecules such as VCAM-1 and ICAM-1 (Geissmann et al., <xref rid="B26" ref-type="bibr">2003</xref>; Tacke et al., <xref rid="B84" ref-type="bibr">2007</xref>; Tuttolomondo et al., <xref rid="B89" ref-type="bibr">2012</xref>; van der Vorst et al., <xref rid="B90" ref-type="bibr">2015</xref>). Following transmigration from the lumen into the intima, these monocytes undergo differentiation into macrophages capable of engulfing the growing pool of apoB-containing LDL and its modified variants (Ley et al., <xref rid="B47" ref-type="bibr">2011</xref>). These differentiated macrophages identify and engulf LDL through expression of scavenger receptors such as oxidized LDL receptor 1 (LOX-1), scavenger receptor A (SRA), and CD36 (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage II) (Yoshida and Kisugi, <xref rid="B104" ref-type="bibr">2010</xref>; Ley et al., <xref rid="B47" ref-type="bibr">2011</xref>).</p><p>Instructively, through the use of CD36/SRA double knockout mice, it has been shown that lipid-laden macrophages will still accumulate in atherosclerotic vessel walls, suggesting additional routes of lipid uptake (Manning-Tobin et al., <xref rid="B57" ref-type="bibr">2009</xref>). Other proposed mechanisms include the capability of macrophages to accumulate LDL via receptor-independent pinocytosis, and the hydrolysis of free cholesterol from LDL aggregates (Barthwal et al., <xref rid="B4" ref-type="bibr">2013</xref>; Bentzon et al., <xref rid="B6" ref-type="bibr">2014</xref>). Cholesterol liberated from lipoproteins taken up by these pathways is transported within the macrophage to the ER where it is esterified to cholesteryl esters by acetyl-coenzyme A:cholesterol acetyltransferase 1 (ACAT1) and neutral cholesterol ester hydrolase (nCEH), while reverse cholesterol transport is controlled by ATP-binding cassette (ABC) transporters including ABCA1 and ABCG1 (Ley et al., <xref rid="B47" ref-type="bibr">2011</xref>). Under healthy conditions, the liberated cholesterol is accepted by HDL particles primary via protein ApoA1, while modification of this protein can produce dysfunctional HDL and produce proatherogenic effects (Fisher et al., <xref rid="B24" ref-type="bibr">2012</xref>). However, under atherosclerotic conditions, macrophages demonstrate both an increase in lipid uptake and inefficient efflux of cholesteryl esters, generating characteristic lipid-laden foam cells (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage II) (Yu et al., <xref rid="B105" ref-type="bibr">2013</xref>). Agonists for the Liver X Receptor (LXR) transcription factors have been proposed as potential therapeutic agents to improve cholesterol efflux and thus reduce foam cell formation, but have also been shown to induce liver steatosis (Levin et al., <xref rid="B44" ref-type="bibr">2005</xref>; Hijmans et al., <xref rid="B33" ref-type="bibr">2015</xref>). Moreover, while efforts have been made to generate synthetic agonists avoiding this effect, recent results have suggested that these agents do not function directly through cholesterol efflux (Kratzer et al., <xref rid="B43" ref-type="bibr">2009</xref>; Kappus et al., <xref rid="B39" ref-type="bibr">2014</xref>). It has been shown that such defects in lipid metabolism can cause ER stress and dysfunction, ultimately leading to apoptosis of the cell (Seimon et al., <xref rid="B79" ref-type="bibr">2010</xref>). Compounding this problem, defects in cholesterol efflux also inhibit efficient efferocytosis (clearance of apoptotic cells by nearby macrophages), leading to an accumulation of apoptotic cells in these regions. The growing population of apoptotic macrophages and foam cells generate the characteristic fatty streak associated with early atherosclerotic plaques (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage III/IV) (Moore and Tabas, <xref rid="B65" ref-type="bibr">2011</xref>; Van Vr&#x000e9; et al., <xref rid="B91" ref-type="bibr">2012</xref>). Apoptotic cells not cleared through phagocytosis then undergo secondary necrosis, releasing cellular debris along with additional oxidized lipids and pro-inflammatory cytokines that contribute to continued inflammation and a growing necrotic core of the more advanced atherosclerotic lesion (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage IV) (Moore and Tabas, <xref rid="B65" ref-type="bibr">2011</xref>; Bentzon et al., <xref rid="B6" ref-type="bibr">2014</xref>).</p><p>Atherogenesis often ceases here, with many lesions progressing no further than the fatty streak, due in large part to various reparative mechanisms such as those initiated by BM-derived progenitor cells (Goldschmidt-Clermont et al., <xref rid="B31" ref-type="bibr">2012</xref>). However, some lesions undergo additional changes within the vascular intima causing a pronounced growth of the plaque and remodeling of the vessel itself. Specifically, macrophages and foam cells within the fatty streak begin releasing inflammatory cytokines (IL-1&#x003b2;, IL-4, and TNF&#x003b1;) that interact with various growth factors [platelet-derived growth factor (PDGF), CD-40] to activate MMPs (Chistiakov et al., <xref rid="B13" ref-type="bibr">2013</xref>). Interestingly, the role of IL-4 has been debated, with early studies demonstrating that IL-4 deficiency in a mouse model of atherosclerosis reduced lesion formation, while later studies found a lack of involvement of this cytokine regardless of disease induction method (Ramji and Davies, <xref rid="B73" ref-type="bibr">2015</xref>). Once activated, these MMPs are responsible for remodeling and weakening the extracellular matrix (ECM) surrounding the vascular smooth muscle cells (VSMC) of the vessel. As a result of the weakened ECM, arterial cells begin to sense transmural pressure as a micro-angioplasty stretch with each pulse, stimulating growth factor release by components of the fatty streak that promote migration of these stretched VSMCs to the growing lesion (Rudijanto, <xref rid="B78" ref-type="bibr">2007</xref>). Under healthy physiological conditions, mature VSMCs rarely undergo proliferation or migration, and exhibit a contractile phenotype (expressing &#x003b1;-smooth muscle actin and calponin) in which they control blood vessel diameter and blood flow through vasodilation or vasoconstriction (Rudijanto, <xref rid="B78" ref-type="bibr">2007</xref>; Zhang et al., <xref rid="B107" ref-type="bibr">2016</xref>). However, in response to injury, VSMCs undergo a transition to a non-contractile or synthetic phenotype, decreasing contractile marker expression, and generating collagen-rich fibrous ECM that eventually represents a major component of this newly formed fibroatheroma (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage V) (Bentzon et al., <xref rid="B6" ref-type="bibr">2014</xref>; Zhang et al., <xref rid="B107" ref-type="bibr">2016</xref>). Complicating this process further, neither elevated levels of cholesterol nor extensive macrophage involvement are strictly required for this VSMC proliferation. As discussed previously, other mechanisms&#x02014;such as epigenetic modification of specific genes associated with SMC proliferation&#x02014;have been shown to be involved in the progression of atherosclerotic plaques (Post et al., <xref rid="B71" ref-type="bibr">1999</xref>; Ying et al., <xref rid="B103" ref-type="bibr">2000</xref>). In addition, deposition and growth of calcium granules may also occur, and has been shown to exhibit both stabilizing and destabilizing effects to the vulnerability of the fibrous cap depending on their extent and location (Li et al., <xref rid="B48" ref-type="bibr">2007</xref>). Indeed vascular calcification, a condition pathognomonic for atherosclerosis, may be quantified in the coronary arteries using computed tomography (CT) to generate a coronary artery calcium (CAC) score that is used in conjunction with the Framingham Risk Score to improve prognostic value of coronary events (Yeboah et al., <xref rid="B102" ref-type="bibr">2012</xref>; Maurovich-Horvat et al., <xref rid="B58" ref-type="bibr">2014</xref>). Modulations of the ECM and proliferation of VSMCs are also required for arterial remodeling, which can be either constrictive or expansive (as a compensatory mechanism to counter atherosclerotic plaque growth) (Wentzel et al., <xref rid="B96" ref-type="bibr">2012</xref>; Bentzon et al., <xref rid="B6" ref-type="bibr">2014</xref>). These advanced plaques also possess the potential to undergo rupture or erosion, exposing the thrombogenic core to the blood flow of the vessel lumen (Figure <xref ref-type="fig" rid="F2">2</xref>, Stage VI). A common trait of plaques vulnerable to rupture is a thin covering of ECs, VSMCs, and ECM&#x02014;termed thin-cap fibroatheromas (TFCAs) and possessing a cap of &#x0003c;65 &#x003bc;m in thickness (Virmani et al., <xref rid="B93" ref-type="bibr">2000</xref>). Activation of MMPs from abundant macrophages present in the plaque may cause degradation of the ECM near the cap, destabilizing EC adhesion and allowing for exposure of the necrotic core, leading to subsequent thrombus formation in the lumen of the vessel. Although this is a rare fate for atherosclerotic plaques (most either do not progress to advanced stages or become stable plaques with caps &#x0003e;65 &#x003bc;m), the subsequent formation of a thrombus from plaque rupture can cause complete occlusion of the local artery, with consequent myocardial infarction and/or sudden cardiac death. Another potential thrombogenic fate of an atherosclerotic plaque is that of plaque erosion, in which a thrombus is formed in the absence of rupture, often with a disrupted endothelium and an enhanced proliferation of VSMCs (Virmani et al., <xref rid="B92" ref-type="bibr">1999</xref>; Braunwald, <xref rid="B7" ref-type="bibr">2013</xref>). Although less common than plaque rupture, plaque erosion has been shown to be more common in women and the elderly, while the underlying mechanisms of plaque erosion are only beginning to be elucidated and still incompletely understood (Libby and Pasterkamp, <xref rid="B51" ref-type="bibr">2015</xref>; Chandran et al., <xref rid="B9" ref-type="bibr">2017</xref>). Regardless of the etiology of the plaque source, the resulting thrombus formed by these processes may also embolize and travel to a secondary vessel causing ischemia, myocardial infarction, or sudden coronary death (Davies, <xref rid="B17" ref-type="bibr">2000</xref>; Bentzon et al., <xref rid="B6" ref-type="bibr">2014</xref>). Alternatively, repeated cycles of clinically silent rupture of the cap followed by healing may contribute to overall plaque growth and luminal stenosis. Another potent source of plaque growth is intraplaque hemorrhage. As the atherosclerotic plaque grows, the region becomes progressively more inflamed as well as hypoxic, inducing angiogenesis and vasa vasorum into the plaque itself. These neovessels have been observed to be fragile and leaky, and are an important source of hemorrhage within the wall of the artery, contributing not only to further inflammation, but also plaque growth and vessel stenosis (Kolodgie et al., <xref rid="B41" ref-type="bibr">2003</xref>). In this way, tissue ischemia caused by luminal stenosis can occur even in the absence of clinically significant rupture (Kovacic and Fuster, <xref rid="B42" ref-type="bibr">2012</xref>).</p></sec><sec id="s4"><title>Control of inflammation: a novel therapeutic opportunity to restore arterial homeostasis</title><p>Atherosclerosis is the most significant human health problem globally. We know today that the disease does not follow a simple, unidirectional progression, and is determined by a myriad of pathways, control mechanisms, and repair processes; these encompass multiple inflammatory molecules, BM-derived progenitor cells, a range of immune cells such as specific monocyte subpopulations, genetic mutations, and epigenetic modifications among numerous other participants both known and those yet to be discovered. Ultimately, however, the clinical result for an immensely large number of individuals is the formation and growth of vascular lesions with the potential to rupture, leading to life-threatening conditions. It is imperative to continue to evolve technological strategies to both predict and detect the formation, progression, and clinical status of these atherosclerotic plaques, while additional details are elucidated regarding the process of disease progression. One example of important progress has been made in the control of inflammation when inflammation is no longer promoting repair, but instead has taken a damaging role for the artery. It was recently reported that a monoclonal antibody against IL1-beta, when injected systemically to patient with CVD and high inflammatory index (CRP levels &#x02265; 2 mg/mL), is capable of reducing risk for coronary events, even with already reduced lipids and had no further effect on lipid levels (Ridker et al., <xref rid="B75" ref-type="bibr">2017</xref>). The role of inflammation is increasingly established in the progression of arterial lesions, and it is useful to consider inflammation in the context of arterial homeostasis. Arterial repair is triggered and controlled by molecules that belong to inflammatory pathways. However, as was hypothesized and subsequently demonstrated in an animal model, the progression of atherosclerotic inflammation is modulated by the presence or the absence of an efficient repair process (Goldschmidt-Clermont et al., <xref rid="B30" ref-type="bibr">2005</xref>). In the presence of BM vascular progenitor cells capable of arterial repair, the artery heals and inflammatory signals subside and vanish. However, as previously discussed, reductions in the availability of BM-derived vascular progenitor cells occurring as a consequence of aging or genetic susceptibility (exhaustion or dysfunction) result in a lack of arterial healing. These reductions can occur either because repair-capable cells are no longer produced effectively by the BM, because the produced cells have become dysfunctional, or a combination thereof. Consequently, inflammatory signals do not subside and vanish, and indeed are heightened to the point where they attract and support monocytes/macrophages and other immune competent cells that further enhance arterial injury (Figure <xref ref-type="fig" rid="F3">3</xref>). Hence, the maintenance of arterial homeostasis is a complex process that must balance injuries to the arterial wall (lipids, smoke, etc.), inflammatory processes required for triggering and supporting arterial repair, and the renewal of BM-derived vascular progenitor cells that are necessary for such repair.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>A visualization of alternative fates of vascular inflammation. In the presence of healthy BM-derived vascular progenitor cells capable of arterial repair, inflammation subsides and vanishes (negative feedback loop), resulting in the maintenance of vascular homeostasis. In the absence of sufficient BM-derived vascular progenitor cells, or if such cells are no longer capable of arterial repair, inflammation continues or even expands, resulting in potential dysfunctional remodeling, continued cell senescence, and propagation of arterial injury (positive feedback loop). However, successful treatments have been established such as statin therapy, which has been shown to reduce circulating LDL-Cholesterol (LDL-C), increase HDL-Cholesterol (HDL-C), reducing inflammation and dysfunctional remodeling (Nozue et al., <xref rid="B67" ref-type="bibr">2013</xref>); Human Allogeneic Mesenchymal Stem Cells (HAMSC) (Tompkins et al., <xref rid="B88" ref-type="bibr">2017</xref>), and possibly other progenitor cells (Song et al., <xref rid="B80" ref-type="bibr">2012</xref>), may be able to reverse arterial tissue senescence and improve arterial repair without affecting circulating lipids; and anti-inflammatory molecules such as Canakinumab have also been shown to reduce destructive inflammation without affecting circulating lipids (Ridker et al., <xref rid="B75" ref-type="bibr">2017</xref>). Hence, our armamentarium to prevent, stabilize or even reverse atherosclerosis and its thromboembolic complications are becoming increasingly effective at promoting arterial homeostasis.</p></caption><graphic xlink:href="fgene-08-00216-g0003"/></fig><p>The example of inflammation suppression in individuals with established CVD is important, as it proves that inflammation can contribute to the disease, and that the control of excessive inflammation via specific agents can lead to consequent reduction in CVD complications. However, this work addresses only one aspect of the overwhelmingly complex disease that is atherosclerosis. As discussed herein, the pathways and players involved in the regulation and progression of this ubiquitous disease are immensely diverse, and subject to continuous reassessment. In much the same way that inflammation has been shown to be involved in the repair of arterial damage or contribute to disease progression when excessive, each component of atherosclerosis may play a critical part depending on the context, while many such components may not yet be fully established. It is instructive that administration of adult mesenchymal stem cells to individuals suffering from aging frailty has been shown, in double blind placebo-controlled prospective randomized trial, to improve functional outcomes of patients, many of which being dependent on the integrity of the cardiovascular system (Tompkins et al., <xref rid="B88" ref-type="bibr">2017</xref>). The concurrent approaches of taming excessive inflammation with specific antagonists, and augmenting the cellular capacity for arterial repair with selected stem cells, in addition to the previously developed armamentarium, may represent the strategies required to restore arterial homeostasis whenever lost, and help to reduce atherosclerosis and its dreadful complications during the twenty-first century.</p></sec><sec id="s5"><title>Author contributions</title><p>All authors contributed equally to the drafting, editing, and final composition of the manuscript. TH: designed and prepared the corresponding figures for the manuscript.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> SD is grateful to the Miller School of Medicine of the University of Miami for the Lucille P. Markey Chair in the Department of Biochemistry and Molecular Biology.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyadevara</surname><given-names>S.</given-names></name><name><surname>Mercanti</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Mackintosh</surname><given-names>S. G.</given-names></name><name><surname>Tackett</surname><given-names>A. J.</given-names></name><name><surname>Prayaga</surname><given-names>S. V.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Age- and hypertension-associated protein aggregates in mouse heart have similar proteomic profiles</article-title>. <source>Hypertension</source>
<volume>67</volume>, <fpage>1006</fpage>&#x02013;<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.06849</pub-id><?supplied-pmid 26975704?><pub-id pub-id-type="pmid">26975704</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>D. J.</given-names></name><name><surname>Childs</surname><given-names>B. G.</given-names></name><name><surname>Durik</surname><given-names>M.</given-names></name><name><surname>Wijers</surname><given-names>M. E.</given-names></name><name><surname>Sieben</surname><given-names>C. J.</given-names></name><name><surname>Zhong</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan</article-title>. <source>Nature</source>
<volume>530</volume>, <fpage>184</fpage>&#x02013;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1038/nature16932</pub-id><?supplied-pmid 26840489?><pub-id pub-id-type="pmid">26840489</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>D. J.</given-names></name><name><surname>Wijshake</surname><given-names>T.</given-names></name><name><surname>Tchkonia</surname><given-names>T.</given-names></name><name><surname>LeBrasseur</surname><given-names>N. K.</given-names></name><name><surname>Childs</surname><given-names>B. G.</given-names></name><name><surname>van de Sluis</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders</article-title>. <source>Nature</source>
<volume>479</volume>, <fpage>232</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1038/nature10600</pub-id><?supplied-pmid 22048312?><pub-id pub-id-type="pmid">22048312</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthwal</surname><given-names>M. K.</given-names></name><name><surname>Anzinger</surname><given-names>J. J.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Bohnacker</surname><given-names>T.</given-names></name><name><surname>Wymann</surname><given-names>M. P.</given-names></name><name><surname>Kruth</surname><given-names>H. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Fluid-phase pinocytosis of native low density lipoprotein promotes murine M-CSF differentiated macrophage foam cell formation</article-title>. <source>PLoS ONE</source>
<volume>8</volume>:<fpage>e58054</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0058054</pub-id><?supplied-pmid 23536783?><pub-id pub-id-type="pmid">23536783</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>E. J.</given-names></name><name><surname>Blaha</surname><given-names>M. J.</given-names></name><name><surname>Chiuve</surname><given-names>S. E.</given-names></name><name><surname>Cushman</surname><given-names>M.</given-names></name><name><surname>Das</surname><given-names>S. R.</given-names></name><name><surname>Deo</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Heart disease and stroke statistics-&#x02212;2017 update: a report from the american heart association</article-title>. <source>Circulation</source>
<volume>135</volume>, <fpage>e146</fpage>&#x02013;<lpage>e603</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000485</pub-id><?supplied-pmid 28122885?><pub-id pub-id-type="pmid">28122885</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentzon</surname><given-names>J. F.</given-names></name><name><surname>Otsuka</surname><given-names>F.</given-names></name><name><surname>Virmani</surname><given-names>R.</given-names></name><name><surname>Falk</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Mechanisms of plaque formation and rupture</article-title>. <source>Circ. Res.</source>
<volume>114</volume>, <fpage>1852</fpage>&#x02013;<lpage>1866</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302721</pub-id><?supplied-pmid 24902970?><pub-id pub-id-type="pmid">24902970</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Coronary plaque erosion: recognition and management</article-title>. <source>JACC Cardiovasc. Imaging</source>
<volume>6</volume>, <fpage>288</fpage>&#x02013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2013.01.003</pub-id><?supplied-pmid 23473110?><pub-id pub-id-type="pmid">23473110</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>M. T.</given-names></name><name><surname>Duckles</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Hsiao</surname><given-names>S. T.</given-names></name><name><surname>Kim</surname><given-names>H. R.</given-names></name><name><surname>Serbanovic-Canic</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Mechanoresponsive networks controlling vascular inflammation</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>34</volume>, <fpage>2199</fpage>&#x02013;<lpage>2205</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303424</pub-id><?supplied-pmid 24947523?><pub-id pub-id-type="pmid">24947523</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>S.</given-names></name><name><surname>Watkins</surname><given-names>J.</given-names></name><name><surname>Abdul-Aziz</surname><given-names>A.</given-names></name><name><surname>Shafat</surname><given-names>M.</given-names></name><name><surname>Calvert</surname><given-names>P. A.</given-names></name><name><surname>Bowles</surname><given-names>K. M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Inflammatory differences in plaque erosion and rupture in patients with ST-segment elevation myocardial infarction</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>6</volume>:<fpage>e005868</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.117.005868</pub-id><?supplied-pmid 28468787?><pub-id pub-id-type="pmid">28468787</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzizisis</surname><given-names>Y. S.</given-names></name><name><surname>Coskun</surname><given-names>A. U.</given-names></name><name><surname>Jonas</surname><given-names>M.</given-names></name><name><surname>Edelman</surname><given-names>E. R.</given-names></name><name><surname>Feldman</surname><given-names>C. L.</given-names></name><name><surname>Stone</surname><given-names>P. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>49</volume>, <fpage>2379</fpage>&#x02013;<lpage>2393</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2007.02.059</pub-id><?supplied-pmid 17599600?><pub-id pub-id-type="pmid">17599600</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>B. G.</given-names></name><name><surname>Baker</surname><given-names>D. J.</given-names></name><name><surname>Wijshake</surname><given-names>T.</given-names></name><name><surname>Conover</surname><given-names>C. A.</given-names></name><name><surname>Campisi</surname><given-names>J.</given-names></name><name><surname>van Deursen</surname><given-names>J. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Senescent intimal foam cells are deleterious at all stages of atherosclerosis</article-title>. <source>Science</source>
<volume>354</volume>, <fpage>472</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf6659</pub-id><?supplied-pmid 27789842?><pub-id pub-id-type="pmid">27789842</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>B. G.</given-names></name><name><surname>Gluscevic</surname><given-names>M.</given-names></name><name><surname>Baker</surname><given-names>D. J.</given-names></name><name><surname>Laberge</surname><given-names>R. M.</given-names></name><name><surname>Marquess</surname><given-names>D.</given-names></name><name><surname>Dananberg</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Senescent cells: an emerging target for diseases of ageing</article-title>. <source>Nat. Rev. Drug. Discov.</source>
<volume>16</volume>, <fpage>718</fpage>&#x02013;<lpage>735</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2017.116</pub-id><?supplied-pmid 28729727?><pub-id pub-id-type="pmid">28729727</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chistiakov</surname><given-names>D. A.</given-names></name><name><surname>Sobenin</surname><given-names>I. A.</given-names></name><name><surname>Orekhov</surname><given-names>A. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Vascular extracellular matrix in atherosclerosis</article-title>. <source>Cardiol. Rev.</source>
<volume>21</volume>, <fpage>270</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1097/CRD.0b013e31828c5ced</pub-id><?supplied-pmid 23422022?><pub-id pub-id-type="pmid">23422022</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>J. J.</given-names></name><name><surname>Chien</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives</article-title>. <source>Physiol. Rev.</source>
<volume>91</volume>, <fpage>327</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00047.2009</pub-id><?supplied-pmid 21248169?><pub-id pub-id-type="pmid">21248169</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>E. M.</given-names></name><name><surname>Thompson</surname><given-names>R. C.</given-names></name><name><surname>Allam</surname><given-names>A. H.</given-names></name><name><surname>Wann</surname><given-names>L. S.</given-names></name><name><surname>Lombardi</surname><given-names>G. P.</given-names></name><name><surname>Sutherland</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Is atherosclerosis fundamental to human aging? Lessons from ancient mummies</article-title>. <source>J. Cardiol.</source>
<volume>63</volume>, <fpage>329</fpage>&#x02013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2013.12.012</pub-id><?supplied-pmid 24582386?><pub-id pub-id-type="pmid">24582386</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Agostino</surname><given-names>R. B.</given-names><suffix>Sr.</suffix></name><name><surname>Vasan</surname><given-names>R. S.</given-names></name><name><surname>Pencina</surname><given-names>M. J.</given-names></name><name><surname>Wolf</surname><given-names>P. A.</given-names></name><name><surname>Cobain</surname><given-names>M.</given-names></name><name><surname>Massaro</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>General cardiovascular risk profile for use in primary care: the framingham heart study</article-title>. <source>Circulation</source>
<volume>117</volume>, <fpage>743</fpage>&#x02013;<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.699579</pub-id><?supplied-pmid 18212285?><pub-id pub-id-type="pmid">18212285</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>M. J.</given-names></name></person-group> (<year>2000</year>). <article-title>The pathophysiology of acute coronary syndromes</article-title>. <source>Heart</source>
<volume>83</volume>, <fpage>361</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1136/heart.83.3.361</pub-id><?supplied-pmid 10677422?><pub-id pub-id-type="pmid">10677422</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>P. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology</article-title>. <source>Nat. Clin. Pract. Cardiovasc. Med.</source>
<volume>6</volume>, <fpage>16</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/ncpcardio1397</pub-id><?supplied-pmid 19029993?><pub-id pub-id-type="pmid">19029993</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>J.</given-names></name><name><surname>Qiu</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Jjingo</surname><given-names>D.</given-names></name><name><surname>Hoffman</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>C. W.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis</article-title>. <source>J. Clin. Invest.</source>
<volume>124</volume>, <fpage>3187</fpage>&#x02013;<lpage>3199</lpage>. <pub-id pub-id-type="doi">10.1172/JCI74792</pub-id><?supplied-pmid 24865430?><pub-id pub-id-type="pmid">24865430</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enos</surname><given-names>W. F.</given-names></name><name><surname>Holmes</surname><given-names>R. H.</given-names></name><name><surname>Beyer</surname><given-names>J.</given-names></name></person-group> (<year>1953</year>). <article-title>Coronary disease among united states soldiers killed in action in korea: preliminary report</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>152</volume>, <fpage>1090</fpage>&#x02013;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1953.03690120006002</pub-id><?supplied-pmid 13052433?><pub-id pub-id-type="pmid">13052433</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eshtehardi</surname><given-names>P.</given-names></name><name><surname>Teng</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>Protective or destructive: high wall shear stress and atherosclerosis</article-title>. <source>Atherosclerosis</source>
<volume>251</volume>, <fpage>501</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.05.046</pub-id><?supplied-pmid 27282831?><pub-id pub-id-type="pmid">27282831</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Manduchi</surname><given-names>E.</given-names></name><name><surname>Civelek</surname><given-names>M.</given-names></name><name><surname>Davies</surname><given-names>P. F.</given-names></name></person-group> (<year>2010</year>). <article-title>MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>13450</fpage>&#x02013;<lpage>13455</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1002120107</pub-id><?supplied-pmid 20624982?><pub-id pub-id-type="pmid">20624982</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ference</surname><given-names>B. A.</given-names></name><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name><name><surname>Graham</surname><given-names>I.</given-names></name><name><surname>Ray</surname><given-names>K. K.</given-names></name><name><surname>Packard</surname><given-names>C. J.</given-names></name><name><surname>Bruckert</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel</article-title>. <source>Eur. Heart J.</source>
<volume>38</volume>, <fpage>2459</fpage>&#x02013;<lpage>2472</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehx144</pub-id><?supplied-pmid 28444290?><pub-id pub-id-type="pmid">28444290</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>E. A.</given-names></name><name><surname>Feig</surname><given-names>J. E.</given-names></name><name><surname>Hewing</surname><given-names>B.</given-names></name><name><surname>Hazen</surname><given-names>S. L.</given-names></name><name><surname>Smith</surname><given-names>J. D.</given-names></name></person-group> (<year>2012</year>). <article-title>High-density lipoprotein function, dysfunction, and reverse cholesterol transport</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>32</volume>, <fpage>2813</fpage>&#x02013;<lpage>2820</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300133</pub-id><?supplied-pmid 23152494?><pub-id pub-id-type="pmid">23152494</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>D.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Lartigue</surname><given-names>L.</given-names></name><name><surname>Bolen</surname><given-names>C. R.</given-names></name><name><surname>Haddad</surname><given-names>F.</given-names></name><name><surname>Gaudilliere</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states</article-title>. <source>Nat. Med.</source>
<volume>23</volume>, <fpage>174</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4267</pub-id><?supplied-pmid 28092664?><pub-id pub-id-type="pmid">28092664</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissmann</surname><given-names>F.</given-names></name><name><surname>Jung</surname><given-names>S.</given-names></name><name><surname>Littman</surname><given-names>D. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title>. <source>Immunity</source>
<volume>19</volume>, <fpage>71</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00174-2</pub-id><?supplied-pmid 12871640?><pub-id pub-id-type="pmid">12871640</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhardt</surname><given-names>T.</given-names></name><name><surname>Ley</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Monocyte trafficking across the vessel wall</article-title>. <source>Cardiovasc. Res.</source>
<volume>107</volume>, <fpage>321</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvv147</pub-id><?supplied-pmid 25990461?><pub-id pub-id-type="pmid">25990461</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>D. C.</given-names><suffix>Jr.</suffix></name><name><surname>Lloyd-Jones</surname><given-names>D. M.</given-names></name><name><surname>Bennett</surname><given-names>G.</given-names></name><name><surname>Coady</surname><given-names>S.</given-names></name><name><surname>D'Agostino</surname><given-names>R. B.</given-names><suffix>Sr.</suffix></name><name><surname>Gibbons</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J. Am. Coll. Cardiol</source>. <volume>63</volume>(<issue>25 Pt B</issue>), <fpage>2935</fpage>&#x02013;<lpage>2959</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2013.11.005</pub-id><?supplied-pmid 24239921?><pub-id pub-id-type="pmid">24239921</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschmidt-Clermont</surname><given-names>P. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis</article-title>. <source>Am. Heart J.</source>
<volume>146</volume>(<issue>4 Suppl.</issue>), <fpage>S5</fpage>&#x02013;<lpage>S12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2003.09.002</pub-id><?supplied-pmid 14564300?><pub-id pub-id-type="pmid">14564300</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschmidt-Clermont</surname><given-names>P. J.</given-names></name><name><surname>Creager</surname><given-names>M. A.</given-names></name><name><surname>Losordo</surname><given-names>D. W.</given-names></name><name><surname>Lam</surname><given-names>G. K.</given-names></name><name><surname>Wassef</surname><given-names>M.</given-names></name><name><surname>Dzau</surname><given-names>V. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Atherosclerosis 2005: recent discoveries and novel hypotheses</article-title>. <source>Circulation</source>
<volume>112</volume>, <fpage>3348</fpage>&#x02013;<lpage>3353</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.577460</pub-id><?supplied-pmid 16301361?><pub-id pub-id-type="pmid">16301361</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschmidt-Clermont</surname><given-names>P. J.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Seo</surname><given-names>D. M.</given-names></name><name><surname>Velazquez</surname><given-names>O. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Atherosclerosis, inflammation, genetics, and stem cells: 2012 update</article-title>. <source>Curr. Atheroscler. Rep.</source>
<volume>14</volume>, <fpage>201</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1007/s11883-012-0244-1</pub-id><?supplied-pmid 22476914?><pub-id pub-id-type="pmid">22476914</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>S.</given-names></name><name><surname>Taylor</surname><given-names>P. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Monocyte and macrophage heterogeneity</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>5</volume>, <fpage>953</fpage>&#x02013;<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1038/nri1733</pub-id><?supplied-pmid 16322748?><pub-id pub-id-type="pmid">16322748</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hijmans</surname><given-names>B. S.</given-names></name><name><surname>Tiemann</surname><given-names>C. A.</given-names></name><name><surname>Grefhorst</surname><given-names>A.</given-names></name><name><surname>Boesjes</surname><given-names>M.</given-names></name><name><surname>van Dijk</surname><given-names>T. H.</given-names></name><name><surname>Tietge</surname><given-names>U. J.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation</article-title>. <source>FASEB J.</source>
<volume>29</volume>, <fpage>1153</fpage>&#x02013;<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1096/fj.14-254656</pub-id><?supplied-pmid 25477282?><pub-id pub-id-type="pmid">25477282</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgendorf</surname><given-names>I.</given-names></name><name><surname>Swirski</surname><given-names>F. K.</given-names></name><name><surname>Robbins</surname><given-names>C. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Monocyte fate in atherosclerosis</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>35</volume>, <fpage>272</fpage>&#x02013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303565</pub-id><?supplied-pmid 25538208?><pub-id pub-id-type="pmid">25538208</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hippisley-Cox</surname><given-names>J.</given-names></name><name><surname>Coupland</surname><given-names>C.</given-names></name><name><surname>Vinogradova</surname><given-names>Y.</given-names></name><name><surname>Robson</surname><given-names>J.</given-names></name><name><surname>Minhas</surname><given-names>R.</given-names></name><name><surname>Sheikh</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2</article-title>. <source>BMJ</source>
<volume>336</volume>, <fpage>1475</fpage>&#x02013;<lpage>1482</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.39609.449676.25</pub-id><?supplied-pmid 18573856?><pub-id pub-id-type="pmid">18573856</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Y. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Atherosclerotic cardiovascular disease beginning in childhood</article-title>. <source>Korean Circ. J.</source>
<volume>40</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4070/kcj.2010.40.1.1</pub-id><?supplied-pmid 20111646?><pub-id pub-id-type="pmid">20111646</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>O. Y.</given-names></name><name><surname>Brown</surname><given-names>A. J.</given-names></name><name><surname>Ahn</surname><given-names>S. G.</given-names></name><name><surname>Veneziani</surname><given-names>A.</given-names></name><name><surname>Giddens</surname><given-names>D. P.</given-names></name><name><surname>Samady</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Association of wall shear stress with coronary plaque progression and transformation</article-title>. <source>Interv. Cardiol. Clin.</source>
<volume>4</volume>, <fpage>491</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.iccl.2015.06.009</pub-id><?supplied-pmid 28581935?><pub-id pub-id-type="pmid">28581935</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S.</given-names></name><name><surname>Natarajan</surname><given-names>P.</given-names></name><name><surname>Silver</surname><given-names>A. J.</given-names></name><name><surname>Gibson</surname><given-names>C. J.</given-names></name><name><surname>Bick</surname><given-names>A. G.</given-names></name><name><surname>Shvartz</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease</article-title>. <source>N. Engl. J. Med</source>. <volume>377</volume>, <fpage>111</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1701719</pub-id><?supplied-pmid 28636844?><pub-id pub-id-type="pmid">28636844</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappus</surname><given-names>M. S.</given-names></name><name><surname>Murphy</surname><given-names>A. J.</given-names></name><name><surname>Abramowicz</surname><given-names>S.</given-names></name><name><surname>Ntonga</surname><given-names>V.</given-names></name><name><surname>Welch</surname><given-names>C. L.</given-names></name><name><surname>Tall</surname><given-names>A. R.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>34</volume>, <fpage>279</fpage>&#x02013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.302781</pub-id><?supplied-pmid 24311381?><pub-id pub-id-type="pmid">24311381</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karra</surname><given-names>R.</given-names></name><name><surname>Vemullapalli</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Herderick</surname><given-names>E. E.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Slosek</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Molecular evidence for arterial repair in atherosclerosis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>102</volume>, <fpage>16789</fpage>&#x02013;<lpage>16794</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0507718102</pub-id><?supplied-pmid 16275914?><pub-id pub-id-type="pmid">16275914</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolodgie</surname><given-names>F. D.</given-names></name><name><surname>Gold</surname><given-names>H. K.</given-names></name><name><surname>Burke</surname><given-names>A. P.</given-names></name><name><surname>Fowler</surname><given-names>D. R.</given-names></name><name><surname>Kruth</surname><given-names>H. S.</given-names></name><name><surname>Weber</surname><given-names>D. K.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Intraplaque hemorrhage and progression of coronary atheroma</article-title>. <source>N. Engl. J. Med.</source>
<volume>349</volume>, <fpage>2316</fpage>&#x02013;<lpage>2325</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa035655</pub-id><?supplied-pmid 14668457?><pub-id pub-id-type="pmid">14668457</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacic</surname><given-names>J. C.</given-names></name><name><surname>Fuster</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Smoking gun theory: angiographically normal or mild coronary plaque as a cause of myocardial infarction</article-title>. <source>Circulation</source>
<volume>126</volume>, <fpage>2918</fpage>&#x02013;<lpage>2920</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.150425</pub-id><?supplied-pmid 23168415?><pub-id pub-id-type="pmid">23168415</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kratzer</surname><given-names>A.</given-names></name><name><surname>Buchebner</surname><given-names>M.</given-names></name><name><surname>Pfeifer</surname><given-names>T.</given-names></name><name><surname>Becker</surname><given-names>T. M.</given-names></name><name><surname>Uray</surname><given-names>G.</given-names></name><name><surname>Miyazaki</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Synthetic LXR agonist attenuates plaque formation in apoE<sup>&#x02212;/&#x02212;</sup> mice without inducing liver steatosis and hypertriglyceridemia</article-title>. <source>J. Lipid. Res.</source>
<volume>50</volume>, <fpage>312</fpage>&#x02013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M800376-JLR200</pub-id><pub-id pub-id-type="pmid">18812595</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>N.</given-names></name><name><surname>Bischoff</surname><given-names>E. D.</given-names></name><name><surname>Daige</surname><given-names>C. L.</given-names></name><name><surname>Thomas</surname><given-names>D.</given-names></name><name><surname>Vu</surname><given-names>C. T.</given-names></name><name><surname>Heyman</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>25</volume>, <fpage>135</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.0000150044.84012.68</pub-id><?supplied-pmid 15539622?><pub-id pub-id-type="pmid">15539622</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Combating the epidemic of heart disease</article-title>. <source>JAMA</source>
<volume>308</volume>, <fpage>2624</fpage>&#x02013;<lpage>2625</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.164971</pub-id><?supplied-pmid 23268522?><pub-id pub-id-type="pmid">23268522</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>K.</given-names></name><name><surname>Laudanna</surname><given-names>C.</given-names></name><name><surname>Cybulsky</surname><given-names>M. I.</given-names></name><name><surname>Nourshargh</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Getting to the site of inflammation: the leukocyte adhesion cascade updated</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>7</volume>, <fpage>678</fpage>&#x02013;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1038/nri2156</pub-id><?supplied-pmid 17717539?><pub-id pub-id-type="pmid">17717539</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>Y. I.</given-names></name><name><surname>Hedrick</surname><given-names>C. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Monocyte and macrophage dynamics during atherogenesis</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>31</volume>, <fpage>1506</fpage>&#x02013;<lpage>1516</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.221127</pub-id><?supplied-pmid 21677293?><pub-id pub-id-type="pmid">21677293</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z. Y.</given-names></name><name><surname>Howarth</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>T.</given-names></name><name><surname>Graves</surname><given-names>M.</given-names></name><name><surname>U-King-Im</surname><given-names>J.</given-names></name><name><surname>Gillard</surname><given-names>J. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Does calcium deposition play a role in the stability of atheroma? Location may be the key</article-title>. <source>Cerebrovasc. Dis.</source>
<volume>24</volume>, <fpage>452</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1159/000108436</pub-id><?supplied-pmid 17878727?><pub-id pub-id-type="pmid">17878727</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Inflammation in atherosclerosis</article-title>. <source>Nature</source>
<volume>420</volume>, <fpage>868</fpage>&#x02013;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1038/nature01323</pub-id><?supplied-pmid 12490960?><pub-id pub-id-type="pmid">12490960</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Assisted living in the atheroma: elderly macrophages promote plaques</article-title>. <source>Cell Metab.</source>
<volume>24</volume>, <fpage>779</fpage>&#x02013;<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.11.013</pub-id><?supplied-pmid 27974178?><pub-id pub-id-type="pmid">27974178</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Pasterkamp</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Requiem for the 'vulnerable plaque'</article-title>. <source>Eur. Heart J.</source>
<volume>36</volume>, <fpage>2984</fpage>&#x02013;<lpage>2987</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehv349</pub-id><?supplied-pmid 26206212?><pub-id pub-id-type="pmid">26206212</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Ridker</surname><given-names>P. M.</given-names></name><name><surname>Hansson</surname><given-names>G. K.</given-names></name><collab>Leducq Transatlantic Network on Atherothrombosis</collab></person-group>. (<year>2009</year>). <article-title>Inflammation in atherosclerosis: from pathophysiology to practice</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>54</volume>, <fpage>2129</fpage>&#x02013;<lpage>2138</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2009.09.009</pub-id><?supplied-pmid 19942084?><pub-id pub-id-type="pmid">19942084</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Ridker</surname><given-names>P. M.</given-names></name><name><surname>Maseri</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Inflammation and atherosclerosis</article-title>. <source>Circulation</source>
<volume>105</volume>, <fpage>1135</fpage>&#x02013;<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1161/hc0902.104353</pub-id><?supplied-pmid 11877368?><pub-id pub-id-type="pmid">11877368</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>M. F.</given-names></name><name><surname>Yancey</surname><given-names>P. G.</given-names></name><name><surname>Davies</surname><given-names>S. S.</given-names></name><name><surname>Jerome</surname><given-names>W. G. J.</given-names></name><name><surname>Linton</surname><given-names>E. F.</given-names></name><name><surname>Vickers</surname><given-names>K. C.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of lipids and lipoproteins in atherosclerosis (2015 update)</article-title>, in <source>Endotext</source>, eds <person-group person-group-type="editor"><name><surname>De Groot</surname><given-names>L. J.</given-names></name><name><surname>Chrousos</surname><given-names>G.</given-names></name><name><surname>Dungan</surname><given-names>K.</given-names></name><name><surname>Feingold</surname><given-names>K. R.</given-names></name><name><surname>Grossman</surname><given-names>A.</given-names></name><name><surname>Hershman</surname><given-names>J. M.</given-names></name><name><surname>Koch</surname><given-names>C.</given-names></name><name><surname>Korbonits</surname><given-names>M.</given-names></name><name><surname>McLachlan</surname><given-names>R.</given-names></name><name><surname>New</surname><given-names>M.</given-names></name><name><surname>Purnell</surname><given-names>J.</given-names></name><name><surname>Rebar</surname><given-names>R.</given-names></name><name><surname>Singer</surname><given-names>F.</given-names></name><name><surname>Vinik</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>South Dartmouth, MA</publisher-loc>: <publisher-name>MDText.com, Inc</publisher-name>.).</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>B. P.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Stemerman</surname><given-names>M. B.</given-names></name><name><surname>Chien</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Shear stress activation of SREBP1 in endothelial cells is mediated by integrins</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>22</volume>, <fpage>76</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1161/hq0102.101822</pub-id><?supplied-pmid 11788464?><pub-id pub-id-type="pmid">11788464</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madonna</surname><given-names>R.</given-names></name><name><surname>Novo</surname><given-names>G.</given-names></name><name><surname>Balistreri</surname><given-names>C. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Cellular and molecular basis of the imbalance between vascular damage and repair in ageing and age-related diseases: as biomarkers and targets for new treatments</article-title>. <source>Mech. Ageing Dev.</source>
<volume>159</volume>, <fpage>22</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.mad.2016.03.005</pub-id><?supplied-pmid 26993150?><pub-id pub-id-type="pmid">26993150</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning-Tobin</surname><given-names>J. J.</given-names></name><name><surname>Moore</surname><given-names>K. J.</given-names></name><name><surname>Seimon</surname><given-names>T. A.</given-names></name><name><surname>Bell</surname><given-names>S. A.</given-names></name><name><surname>Sharuk</surname><given-names>M.</given-names></name><name><surname>Alvarez-Leite</surname><given-names>J. I.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>29</volume>, <fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.108.176644</pub-id><?supplied-pmid 18948635?><pub-id pub-id-type="pmid">18948635</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurovich-Horvat</surname><given-names>P.</given-names></name><name><surname>Ferencik</surname><given-names>M.</given-names></name><name><surname>Voros</surname><given-names>S.</given-names></name><name><surname>Merkely</surname><given-names>B.</given-names></name><name><surname>Hoffmann</surname><given-names>U.</given-names></name></person-group> (<year>2014</year>). <article-title>Comprehensive plaque assessment by coronary CT angiography</article-title>. <source>Nat. Rev. Cardiol.</source>
<volume>11</volume>, <fpage>390</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2014.60</pub-id><?supplied-pmid 24755916?><pub-id pub-id-type="pmid">24755916</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCurdy</surname><given-names>E.</given-names></name></person-group> (<year>1923</year>). <source>Leonardo da Vinci's Note-Books: Arranged and Rendered into English</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Empire state book company</publisher-name>.</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>H. C.</given-names><suffix>Jr.</suffix></name><name><surname>McMahan</surname><given-names>C. A.</given-names></name><name><surname>Herderick</surname><given-names>E. E.</given-names></name><name><surname>Malcom</surname><given-names>G. T.</given-names></name><name><surname>Tracy</surname><given-names>R. E.</given-names></name><name><surname>Strong</surname><given-names>J. P.</given-names></name></person-group> (<year>2000</year>). <article-title>Origin of atherosclerosis in childhood and adolescence</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>72</volume>(<issue>5 Suppl</issue>.), <fpage>1307S</fpage>&#x02212;<lpage>1315S</lpage>. <?supplied-pmid 11063473?><pub-id pub-id-type="pmid">11063473</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>J. L.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Hermonat</surname><given-names>P. L.</given-names></name><name><surname>Romeo</surname><given-names>F.</given-names></name><name><surname>Novelli</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders</article-title>. <source>Cardiovasc. Res.</source>
<volume>69</volume>, <fpage>36</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardiores.2005.09.006</pub-id><?supplied-pmid 16324688?><pub-id pub-id-type="pmid">16324688</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>J. L.</given-names></name><name><surname>Sanada</surname><given-names>N.</given-names></name><name><surname>Hu</surname><given-names>C. P.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Dandapat</surname><given-names>A.</given-names></name><name><surname>Sugawara</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet</article-title>. <source>Circ. Res.</source>
<volume>100</volume>, <fpage>1634</fpage>&#x02013;<lpage>1642</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.149724</pub-id><?supplied-pmid 17478727?><pub-id pub-id-type="pmid">17478727</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Members</surname><given-names>W. G.</given-names></name><name><surname>Mozaffarian</surname><given-names>D.</given-names></name><name><surname>Benjamin</surname><given-names>E. J.</given-names></name><name><surname>Go</surname><given-names>A. S.</given-names></name><name><surname>Arnett</surname><given-names>D. K.</given-names></name><name><surname>Blaha</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Heart disease and stroke statistics-2016 update: a report from the american heart association</article-title>. <source>Circulation</source>
<volume>133</volume>, <fpage>e38</fpage>&#x02013;<lpage>e360</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000350</pub-id><pub-id pub-id-type="pmid">26673558</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>S.</given-names></name><name><surname>Goyal</surname><given-names>T.</given-names></name><name><surname>Mehta</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Oxidized, LDL, LOX-1 and atherosclerosis</article-title>. <source>Cardiovasc. Drugs Ther.</source>
<volume>25</volume>, <fpage>419</fpage>&#x02013;<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1007/s10557-011-6341-5</pub-id><?supplied-pmid 21947818?><pub-id pub-id-type="pmid">21947818</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>K. J.</given-names></name><name><surname>Tabas</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>Macrophages in the pathogenesis of atherosclerosis</article-title>. <source>Cell</source>
<volume>145</volume>, <fpage>341</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.04.005</pub-id><?supplied-pmid 21529710?><pub-id pub-id-type="pmid">21529710</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myerburg</surname><given-names>R. J.</given-names></name><name><surname>Junttila</surname><given-names>M. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Sudden cardiac death caused by coronary heart disease</article-title>. <source>Circulation</source>
<volume>125</volume>, <fpage>1043</fpage>&#x02013;<lpage>1052</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.023846</pub-id><?supplied-pmid 22371442?><pub-id pub-id-type="pmid">22371442</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozue</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Tohyama</surname><given-names>S.</given-names></name><name><surname>Fukui</surname><given-names>K.</given-names></name><name><surname>Umezawa</surname><given-names>S.</given-names></name><name><surname>Onishi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Comparison of change in coronary atherosclerosis in patients with stable vs. unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] study)</article-title>. <source>Am. J. Cardiol.</source>
<volume>111</volume>, <fpage>923</fpage>&#x02013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2012.12.008</pub-id><pub-id pub-id-type="pmid">23337838</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress</article-title>. <source>Antioxid. Redox Signal.</source>
<volume>11</volume>, <fpage>1669</fpage>&#x02013;<lpage>1682</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2009.2487</pub-id><?supplied-pmid 19309258?><pub-id pub-id-type="pmid">19309258</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passlick</surname><given-names>B.</given-names></name><name><surname>Flieger</surname><given-names>D.</given-names></name><name><surname>Ziegler-Heitbrock</surname><given-names>H. W.</given-names></name></person-group> (<year>1989</year>). <article-title>Identification and characterization of a novel monocyte subpopulation in human peripheral blood</article-title>. <source>Blood</source>
<volume>74</volume>, <fpage>2527</fpage>&#x02013;<lpage>2534</lpage>. <?supplied-pmid 2478233?><pub-id pub-id-type="pmid">2478233</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirillo</surname><given-names>A.</given-names></name><name><surname>Norata</surname><given-names>G. D.</given-names></name><name><surname>Catapano</surname><given-names>A. L.</given-names></name></person-group> (<year>2013</year>). <article-title>LOX-1, OxLDL, and atherosclerosis</article-title>. <source>Mediators Inflamm.</source>
<volume>2013</volume>:<fpage>152786</fpage>. <pub-id pub-id-type="doi">10.1155/2013/152786</pub-id><?supplied-pmid 23935243?><pub-id pub-id-type="pmid">23935243</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>W. S.</given-names></name><name><surname>Goldschmidt-Clermont</surname><given-names>P. J.</given-names></name><name><surname>Wilhide</surname><given-names>C. C.</given-names></name><name><surname>Heldman</surname><given-names>A. W.</given-names></name><name><surname>Sussman</surname><given-names>M. S.</given-names></name><name><surname>Ouyang</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>1999</year>). <article-title>Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system</article-title>. <source>Cardiovasc. Res.</source>
<volume>43</volume>, <fpage>985</fpage>&#x02013;<lpage>991</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6363(99)00153-4</pub-id><?supplied-pmid 10615426?><pub-id pub-id-type="pmid">10615426</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintar</surname><given-names>A.</given-names></name><name><surname>McArdle</surname><given-names>S.</given-names></name><name><surname>Wolf</surname><given-names>D.</given-names></name><name><surname>Marki</surname><given-names>A.</given-names></name><name><surname>Ehinger</surname><given-names>E.</given-names></name><name><surname>Vassallo</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Endothelial protective monocyte patrolling in large arteries intensified by western diet and atherosclerosis</article-title>. <source>Circ. Res.</source>
<volume>120</volume>, <fpage>1789</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310739</pub-id><?supplied-pmid 28302649?><pub-id pub-id-type="pmid">28302649</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramji</surname><given-names>D. P.</given-names></name><name><surname>Davies</surname><given-names>T. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets</article-title>. <source>Cytokine Growth Factor Rev.</source>
<volume>26</volume>, <fpage>673</fpage>&#x02013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.04.003</pub-id><?supplied-pmid 26005197?><pub-id pub-id-type="pmid">26005197</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauscher</surname><given-names>F. M.</given-names></name><name><surname>Goldschmidt-Clermont</surname><given-names>P. J.</given-names></name><name><surname>Davis</surname><given-names>B. H.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Gregg</surname><given-names>D.</given-names></name><name><surname>Ramaswami</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Aging, progenitor cell exhaustion, and atherosclerosis</article-title>. <source>Circulation</source>
<volume>108</volume>, <fpage>457</fpage>&#x02013;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000082924.75945.48</pub-id><?supplied-pmid 12860902?><pub-id pub-id-type="pmid">12860902</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P. M.</given-names></name><name><surname>Everett</surname><given-names>B. M.</given-names></name><name><surname>Thuren</surname><given-names>T.</given-names></name><name><surname>MacFadyen</surname><given-names>J. G.</given-names></name><name><surname>Chang</surname><given-names>W. H.</given-names></name><name><surname>Ballantyne</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title>. <source>N. Engl. J. Med</source>. <volume>377</volume>, <fpage>1119</fpage>&#x02013;<lpage>1131</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><?supplied-pmid 28845751?><pub-id pub-id-type="pmid">28845751</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenson</surname><given-names>R. S.</given-names></name><name><surname>Brewer</surname><given-names>H. B.</given-names><suffix>Jr.</suffix></name><name><surname>Ansell</surname><given-names>B. J.</given-names></name><name><surname>Barter</surname><given-names>P.</given-names></name><name><surname>Chapman</surname><given-names>M. J.</given-names></name><name><surname>Heinecke</surname><given-names>J. W.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Dysfunctional HDL and atherosclerotic cardiovascular disease</article-title>. <source>Nat. Rev. Cardiol.</source>
<volume>13</volume>, <fpage>48</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2015.124</pub-id><?supplied-pmid 26323267?><pub-id pub-id-type="pmid">26323267</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R.</given-names></name></person-group> (<year>1999</year>). <article-title>Atherosclerosis&#x02013;an inflammatory disease</article-title>. <source>N. Engl. J. Med.</source>
<volume>340</volume>, <fpage>115</fpage>&#x02013;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199901143400207</pub-id><?supplied-pmid 9887164?><pub-id pub-id-type="pmid">9887164</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudijanto</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis</article-title>. <source>Acta Med. Indones.</source>
<volume>39</volume>, <fpage>86</fpage>&#x02013;<lpage>93</lpage>. <?supplied-pmid 17933075?><pub-id pub-id-type="pmid">17933075</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seimon</surname><given-names>T. A.</given-names></name><name><surname>Nadolski</surname><given-names>M. J.</given-names></name><name><surname>Liao</surname><given-names>X.</given-names></name><name><surname>Magallon</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>M.</given-names></name><name><surname>Feric</surname><given-names>N. T.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress</article-title>. <source>Cell Metab.</source>
<volume>12</volume>, <fpage>467</fpage>&#x02013;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2010.09.010</pub-id><?supplied-pmid 21035758?><pub-id pub-id-type="pmid">21035758</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Seo</surname><given-names>P.</given-names></name><name><surname>Herderick</surname><given-names>E.</given-names></name><name><surname>Webster</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Will periodic intravenous injections of conditioned bone marrow cells effectively reduce atherosclerosis?</article-title>
<source>Antioxid Redox. Signal.</source>
<volume>16</volume>, <fpage>85</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2011.4139</pub-id><?supplied-pmid 21740335?><pub-id pub-id-type="pmid">21740335</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stansfield</surname><given-names>B. K.</given-names></name><name><surname>Ingram</surname><given-names>D. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Clinical significance of monocyte heterogeneity</article-title>. <source>Clin. Transl. Med.</source>
<volume>4</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s40169-014-0040-3</pub-id><?supplied-pmid 25852821?><pub-id pub-id-type="pmid">25852821</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steensma</surname><given-names>D. P.</given-names></name><name><surname>Bejar</surname><given-names>R.</given-names></name><name><surname>Jaiswal</surname><given-names>S.</given-names></name><name><surname>Lindsley</surname><given-names>R. C.</given-names></name><name><surname>Sekeres</surname><given-names>M. A.</given-names></name><name><surname>Hasserjian</surname><given-names>R. P.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes</article-title>. <source>Blood</source>
<volume>126</volume>, <fpage>9</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2015-03-631747</pub-id><?supplied-pmid 25931582?><pub-id pub-id-type="pmid">25931582</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swirski</surname><given-names>F. K.</given-names></name><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Aikawa</surname><given-names>E.</given-names></name><name><surname>Alcaide</surname><given-names>P.</given-names></name><name><surname>Luscinskas</surname><given-names>F. W.</given-names></name><name><surname>Weissleder</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata</article-title>. <source>J. Clin. Invest.</source>
<volume>117</volume>, <fpage>195</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1172/JCI29950</pub-id><?supplied-pmid 17200719?><pub-id pub-id-type="pmid">17200719</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacke</surname><given-names>F.</given-names></name><name><surname>Alvarez</surname><given-names>D.</given-names></name><name><surname>Kaplan</surname><given-names>T. J.</given-names></name><name><surname>Jakubzick</surname><given-names>C.</given-names></name><name><surname>Spanbroek</surname><given-names>R.</given-names></name><name><surname>Llodra</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques</article-title>. <source>J. Clin. Invest.</source>
<volume>117</volume>, <fpage>185</fpage>&#x02013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1172/JCI28549</pub-id><?supplied-pmid 17200718?><pub-id pub-id-type="pmid">17200718</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>G. S.</given-names></name><name><surname>Wann</surname><given-names>L. S.</given-names></name><name><surname>Allam</surname><given-names>A. H.</given-names></name><name><surname>Thompson</surname><given-names>R. C.</given-names></name><name><surname>Michalik</surname><given-names>D. E.</given-names></name><name><surname>Sutherland</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Why did ancient people have atherosclerosis?: from autopsies to computed tomography to potential causes</article-title>. <source>Glob. Heart</source>
<volume>9</volume>, <fpage>229</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.gheart.2014.04.002</pub-id><?supplied-pmid 25667093?><pub-id pub-id-type="pmid">25667093</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>G.</given-names></name><name><surname>Tacke</surname><given-names>R.</given-names></name><name><surname>Hedrick</surname><given-names>C. C.</given-names></name><name><surname>Hanna</surname><given-names>R. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Nonclassical patrolling monocyte function in the vasculature</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>35</volume>, <fpage>1306</fpage>&#x02013;<lpage>1316</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304650</pub-id><?supplied-pmid 25838429?><pub-id pub-id-type="pmid">25838429</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>R. C.</given-names></name><name><surname>Allam</surname><given-names>A. H.</given-names></name><name><surname>Lombardi</surname><given-names>G. P.</given-names></name><name><surname>Wann</surname><given-names>L. S.</given-names></name><name><surname>Sutherland</surname><given-names>M. L.</given-names></name><name><surname>Sutherland</surname><given-names>J. D.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Atherosclerosis across 4000 years of human history: the horus study of four ancient populations</article-title>. <source>Lancet</source>
<volume>381</volume>, <fpage>1211</fpage>&#x02013;<lpage>1222</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60598-X</pub-id><?supplied-pmid 23489753?><pub-id pub-id-type="pmid">23489753</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tompkins</surname><given-names>B. A.</given-names></name><name><surname>DiFede</surname><given-names>D. L.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Landin</surname><given-names>A. M.</given-names></name><name><surname>Schulman</surname><given-names>I. H.</given-names></name><name><surname>Pujol</surname><given-names>M. V.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Allogenic mesenchymal stem cells ameliorate aging frailty a phase ii randomized, double-blinded, placebo-controlled clinical trial</article-title>. <source>J. Gerontol. A Biol. Sci. Med. Sci.</source>
<volume>72</volume>, <fpage>1513</fpage>&#x02013;<lpage>1522</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/glx137</pub-id><pub-id pub-id-type="pmid">28977399</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuttolomondo</surname><given-names>A.</given-names></name><name><surname>Di Raimondo</surname><given-names>D.</given-names></name><name><surname>Pecoraro</surname><given-names>R.</given-names></name><name><surname>Arnao</surname><given-names>V.</given-names></name><name><surname>Pinto</surname><given-names>A.</given-names></name><name><surname>Licata</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Atherosclerosis as an inflammatory disease</article-title>. <source>Curr. Pharm. Des.</source>
<volume>18</volume>, <fpage>4266</fpage>&#x02013;<lpage>4288</lpage>. <pub-id pub-id-type="doi">10.2174/138161212802481237</pub-id><pub-id pub-id-type="pmid">22390643</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vorst</surname><given-names>E. P.</given-names></name><name><surname>D&#x000f6;ring</surname><given-names>Y.</given-names></name><name><surname>Weber</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Chemokines and their receptors in Atherosclerosis</article-title>. <source>J. Mol. Med.</source>
<volume>93</volume>, <fpage>963</fpage>&#x02013;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-015-1317-8</pub-id><?supplied-pmid 26175090?><pub-id pub-id-type="pmid">26175090</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Vr&#x000e9;</surname><given-names>E. A.</given-names></name><name><surname>Ait-Oufella</surname><given-names>H.</given-names></name><name><surname>Tedgui</surname><given-names>A.</given-names></name><name><surname>Mallat</surname><given-names>Z.</given-names></name></person-group> (<year>2012</year>). <article-title>Apoptotic cell death and efferocytosis in atherosclerosis</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>32</volume>, <fpage>887</fpage>&#x02013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.224873</pub-id><?supplied-pmid 22328779?><pub-id pub-id-type="pmid">22328779</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>R.</given-names></name><name><surname>Burke</surname><given-names>A. P.</given-names></name><name><surname>Farb</surname><given-names>A.</given-names></name></person-group> (<year>1999</year>). <article-title>Plaque rupture and plaque erosion</article-title>. <source>Thromb. Haemost.</source>
<volume>82</volume>(<issue>Suppl. 1</issue>), <fpage>1</fpage>&#x02013;<lpage>3</lpage>. <?supplied-pmid 10695476?><pub-id pub-id-type="pmid">10695476</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>R.</given-names></name><name><surname>Kolodgie</surname><given-names>F. D.</given-names></name><name><surname>Burke</surname><given-names>A. P.</given-names></name><name><surname>Farb</surname><given-names>A.</given-names></name><name><surname>Schwartz</surname><given-names>S. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>20</volume>, <fpage>1262</fpage>&#x02013;<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.20.5.1262</pub-id><?supplied-pmid 10807742?><pub-id pub-id-type="pmid">10807742</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warboys</surname><given-names>C. M.</given-names></name><name><surname>Amini</surname><given-names>N.</given-names></name><name><surname>de Luca</surname><given-names>A.</given-names></name><name><surname>Evans</surname><given-names>P. C.</given-names></name></person-group> (<year>2011</year>). <article-title>The role of blood flow in determining the sites of atherosclerotic plaques</article-title>. <source>F1000 Med. Rep</source>. <volume>3</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.3410/M3-5</pub-id><?supplied-pmid 21654925?><pub-id pub-id-type="pmid">21654925</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webber</surname><given-names>B. J.</given-names></name><name><surname>Seguin</surname><given-names>P. G.</given-names></name><name><surname>Burnett</surname><given-names>D. G.</given-names></name><name><surname>Clark</surname><given-names>L. L.</given-names></name><name><surname>Otto</surname><given-names>J. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011</article-title>. <source>JAMA</source>
<volume>308</volume>, <fpage>2577</fpage>&#x02013;<lpage>2583</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.70830</pub-id><?supplied-pmid 23268516?><pub-id pub-id-type="pmid">23268516</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentzel</surname><given-names>J. J.</given-names></name><name><surname>Chatzizisis</surname><given-names>Y. S.</given-names></name><name><surname>Gijsen</surname><given-names>F. J.</given-names></name><name><surname>Giannoglou</surname><given-names>G. D.</given-names></name><name><surname>Feldman</surname><given-names>C. L.</given-names></name><name><surname>Stone</surname><given-names>P. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions</article-title>. <source>Cardiovasc. Res.</source>
<volume>96</volume>, <fpage>234</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvs217</pub-id><?supplied-pmid 22752349?><pub-id pub-id-type="pmid">22752349</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>G.</given-names></name><name><surname>Grundtman</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <source>Inflammation and Atherosclerosis.</source>
<publisher-loc>Wien</publisher-loc>: <publisher-name>Springer</publisher-name>.</mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>M. S.</given-names></name><name><surname>Patterson</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Proteotoxicity and cardiac dysfunction&#x02013;Alzheimer's disease of the heart?</article-title>
<source>N. Engl. J. Med.</source>
<volume>368</volume>, <fpage>455</fpage>&#x02013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1106180</pub-id><?supplied-pmid 23363499?><pub-id pub-id-type="pmid">23363499</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woollard</surname><given-names>K. J.</given-names></name><name><surname>Geissmann</surname><given-names>F.</given-names></name></person-group> (<year>2010</year>). <article-title>Monocytes in atherosclerosis: subsets and functions</article-title>. <source>Nat. Rev. Cardiol.</source>
<volume>7</volume>, <fpage>77</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2009.228</pub-id><?supplied-pmid 20065951?><pub-id pub-id-type="pmid">20065951</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>T. Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W. C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility</article-title>. <source>Circulation</source>
<volume>128</volume>, <fpage>632</fpage>&#x02013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002714</pub-id><?supplied-pmid 23838163?><pub-id pub-id-type="pmid">23838163</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2009</year>). <article-title>Disturbed flow-enhanced endothelial turnover in atherosclerosis</article-title>. <source>Trends Cardiovasc. Med.</source>
<volume>19</volume>, <fpage>191</fpage>&#x02013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcm.2009.12.002</pub-id><?supplied-pmid 20211434?><pub-id pub-id-type="pmid">20211434</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeboah</surname><given-names>J.</given-names></name><name><surname>McClelland</surname><given-names>R. L.</given-names></name><name><surname>Polonsky</surname><given-names>T. S.</given-names></name><name><surname>Burke</surname><given-names>G. L.</given-names></name><name><surname>Sibley</surname><given-names>C. T.</given-names></name><name><surname>O'Leary</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals</article-title>. <source>JAMA</source>
<volume>308</volume>, <fpage>788</fpage>&#x02013;<lpage>795</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.9624</pub-id><?supplied-pmid 22910756?><pub-id pub-id-type="pmid">22910756</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>A. K.</given-names></name><name><surname>Hassanain</surname><given-names>H. H.</given-names></name><name><surname>Roos</surname><given-names>C. M.</given-names></name><name><surname>Smiraglia</surname><given-names>D. J.</given-names></name><name><surname>Issa</surname><given-names>J. J.</given-names></name><name><surname>Michler</surname><given-names>R. E.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells</article-title>. <source>Cardiovasc. Res.</source>
<volume>46</volume>, <fpage>172</fpage>&#x02013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/S0008-6363(00)00004-3</pub-id><?supplied-pmid 10727665?><pub-id pub-id-type="pmid">10727665</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Kisugi</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Mechanisms of LDL oxidation</article-title>. <source>Clin. Chim. Acta</source>
<volume>411</volume>, <fpage>1875</fpage>&#x02013;<lpage>1882</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2010.08.038</pub-id><?supplied-pmid 20816951?><pub-id pub-id-type="pmid">20816951</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X. H.</given-names></name><name><surname>Fu</surname><given-names>Y. C.</given-names></name><name><surname>Zhang</surname><given-names>D. W.</given-names></name><name><surname>Yin</surname><given-names>K.</given-names></name><name><surname>Tang</surname><given-names>C. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Foam cells in atherosclerosis</article-title>. <source>Clin. Chim. Acta</source>
<volume>424</volume>, <fpage>245</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2013.06.006</pub-id><?supplied-pmid 23782937?><pub-id pub-id-type="pmid">23782937</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S.</given-names></name><name><surname>Hawken</surname><given-names>S.</given-names></name><name><surname>Ounpuu</surname><given-names>S.</given-names></name><name><surname>Dans</surname><given-names>T.</given-names></name><name><surname>Avezum</surname><given-names>A.</given-names></name><name><surname>Lanas</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title>. <source>Lancet</source>
<volume>364</volume>, <fpage>937</fpage>&#x02013;<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17018-9</pub-id><?supplied-pmid 15364185?><pub-id pub-id-type="pmid">15364185</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. N.</given-names></name><name><surname>Xie</surname><given-names>B. D.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>S. L.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Phenotypic switching of vascular smooth muscle cells in the 'normal region' of aorta from atherosclerosis patients is regulated by miR-145</article-title>. <source>J. Cell. Mol. Med.</source>
<volume>20</volume>, <fpage>1049</fpage>&#x02013;<lpage>1061</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.12825</pub-id><?supplied-pmid 26992033?><pub-id pub-id-type="pmid">26992033</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler-Heitbrock</surname><given-names>L.</given-names></name><name><surname>Ancuta</surname><given-names>P.</given-names></name><name><surname>Crowe</surname><given-names>S.</given-names></name><name><surname>Dalod</surname><given-names>M.</given-names></name><name><surname>Grau</surname><given-names>V.</given-names></name><name><surname>Hart</surname><given-names>D. N.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Nomenclature of monocytes and dendritic cells in blood</article-title>. <source>Blood</source>
<volume>116</volume>, <fpage>e74</fpage>&#x02013;<lpage>e80</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-02-258558</pub-id><?supplied-pmid 20628149?><pub-id pub-id-type="pmid">20628149</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zieske</surname><given-names>A. W.</given-names></name><name><surname>Malcom</surname><given-names>G. T.</given-names></name><name><surname>Strong</surname><given-names>J. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Natural history and risk factors of atherosclerosis in children and youth: the PDAY study</article-title>. <source>Pediatr. Pathol. Mol. Med.</source>
<volume>21</volume>, <fpage>213</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1080/pdp.21.2.213.237</pub-id><?supplied-pmid 11942537?><pub-id pub-id-type="pmid">11942537</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zink</surname><given-names>A.</given-names></name><name><surname>Wann</surname><given-names>L. S.</given-names></name><name><surname>Thompson</surname><given-names>R. C.</given-names></name><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Maixner</surname><given-names>F.</given-names></name><name><surname>Allam</surname><given-names>A. H.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Genomic correlates of atherosclerosis in ancient humans</article-title>. <source>Glob. Heart</source>
<volume>9</volume>, <fpage>203</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.gheart.2014.03.2453</pub-id><?supplied-pmid 25667090?><pub-id pub-id-type="pmid">25667090</pub-id></mixed-citation></ref></ref-list></back></article>